Use of convalescent plasma in COVID-19, a bioethical perspective by Zúñiga Lara, Elsa Mariana et al.
                                             Eubios Journal of Asian and International Bioethics 31(7) (November 2021) 336
 
Egg	 (DIABEGG)	 Study—randomized	 weight-loss	 and	 follow-
up	phase.	American	Journal	Clincal	Nutrition,	107:921–931.	
15.	 Krista	 A,	 Varady	 VT,	 Monica	 DC,	 Klempel	 MH,	 Rani	 CCM,	
Sylvia	 S.	 2015.	 Effects	 of	 weight	 loss	 via	 high	 fat	 vs	 low	 fat	
alternate	 day	 fasting	 diets	 on	 free	 fatty	 acid	 profiles.	 In	
Scientific	Reports.	Nature	research	Journal,	5:8806.	
16.	 Kursat	 K,	 Ozdemir	 N.	 2012.	 The	 Effect	 of	 Nutritional	
Elements	on	the	Immune	System.	Journal	of	Obesity	&	Weight	
Loss	Therapy,		2:9:1-6.	
17.	Victor	WR,	 David	 AB,	 Kathleen	MB,	 Peter	 JK,	 Anthony	 PW.	





19.	 Chearskul	 S,	 Delbridge	 E,	 Shulkes	 A,	 Proiett	 J,	 Kriketos	 A.	
2008.	 Effect	 of	 weight	 loss	 and	 ketosis	 on	 postprandial	
cholecystokinin	and	free	fatty	acid	concentrations.	 	American	
Journal	Clinical	Nutrition,	87:	1238–1246.	
20.	 Albahrani	 AA,	 Greaves	 RF.	 2016.	 Fat-Soluble	 Vitamins:	
C l inical	 Indicat ions	 and	 Current	 Chal lenges	 for	
Chromatographic	 Measurement.	 Clin	 Biochem	 Rev ,	
37(1):27-47.	
21.	Harvard	T	H	Chan	School	of	Public	Health.	2020.	Food	safety,	
nutrition,	 and	 wellness	 during	 COVID-19.	 https://
www.hsph.harvard.edu/nutritionsource/2020/03/25/food-
safety-nutrition-and-wellness-during-covid-19/	(2	July	2020)	
22.	 Plum	 LA,	 DeLuca	 HF.	 2010.	 Vitamin	 D,	 disease	 and	
therapeutic	 opportunities.	 Nature	 Reviews	 Drug	 Discovery.	
9:941–55.		
23.	 Arihiro	 S,	 Nakashima	 A,	 Matsuoka	 M,	 Suto	 S,	 Uchiyama	 K,	
Kato	T,	Mitobe	 J,	 Komoike	N,	 Itagaki	M,	Miyakawa	Y,	 Koid	 S.	
(2019)	 Randomized	 trial	 of	 vitamin	 D	 supplementation	 to	
prevent	seasonal	influenza	and	upper	respiratory	infection	in	
patients	 with	 inflammatory	 bowel	 disease.	 InSlammatory	
bowel	diseases.	4;	25(6):1088-95.	
24.Martineau	AR,	 Jolliffe	 DA,	Hooper	 RL,	 Greenberg	 L,	 Aloia	 JF,	
Bergman	P,	Dubnov-Raz	G,	 Esposito	 S,	 Ganmaa	D,	Ginde	AA,	
Goodall	 EC.	 2017.	 Vitamin	 D	 supplementation	 to	 prevent	
acute	 respiratory	 tract	 infections:	 systematic	 review	 and	
meta-analysis	 of	 individual	 participant	 data.	 British	 Medical	
Journal,	15;	356:i6583.	
25.	Zhou	J,	Du	J,	Huang	L,	Wang	Y,	Shi	Y,	Lin	H.	2018.	Preventive	
effects	 of	 vitamin	 D	 on	 seasonal	 influenza	 A	 in	 infants:	 a	




risk	 factors	 are	 not	 different	 following	 weight	 loss	 on	
carbohydrate-restricted	diets	high	in	either	monounsaturated	
fat	 or	 protein	 in	 obese	 hyperinsulinaemic	men	 and	women.	
British	Journal	of	Nutrition,	97,	405–410,		
27.	 WHO.	 2020.	 Healthy	 diet.	 https://www.who.int/en/news-
room/fact-sheets/detail/healthy-diet	(3	July	2020).	
28.	US	Department	of	Agriculture.	Agricultural	Research	Service.	
2010.	 USDA	 National	 Nutrient	 Database	 for	 Standard	
Reference,	 Release	 23,	 Nutrient	 Data	 Laboratory.	 http://
www.ars.usda.gov/nutrientdata	(July	2,	2020).	
29.	Times.	Whole	eggs	or	egg	white:	Should	you	avoid	egg	yolks	




30.	 Ann	 FLB.	 2008.	 How	 the	 Ideology	 of	 Low	 Fat	 Conquered?	
America	 J	History	 of	Medicine	 and	Allied	 sciences,	 63;	 	 2:139	
-77.	
31.	 National	 Heart	 Foundation	 of	 Australia.	 2009.	 Position	
statement:	 dietary	 fats	 and	 dietary	 cholesterol	 for	




32.	 Evert	 AB,	 Boucher	 JL,	 Cypress	 M,	 Dunbar	 SA,	 Franz	 MJ,	
Mayer-Davis	EJ,	Neumiller	JJ,	Nwankwo	R,	Verdi	CL,	Urbanski	
P	 et	 al.	 2013.	 Nutrition	 therapy	 recommendations	 for	 the	
management	 of	 adults	with	 diabetes.	Diabetes	 Care,	 36(11),	
3821-3842.	http://doi.org/10.2337/dc13-2042	
33.	 Akonor	 A,	 Akonor	 PT.	 2014.	 Egg	 consumption:	 patterns,	
preferences	 and	 perceptions	 among	 consumers	 in	 Accra	
metropolitan	area.	International	Food	Research	Journal,	21(4):	
1457-1463.		
34.	 Bejaei	 M,	 Wiseman	 K,	 Cheng	 KM.	 2011.	 Influences	 of	
demographic	 characteristics,	 attitudes,	 and	 preferences	 of	
consumers	 on	 table	 egg	 consumption	 in	 British	 Columbia,	
Canada.	 Poultry	 science,	 90(5),	 1088–1095.	 https://doi.org/
10.3382/ps.2010-01129	.		
	 	 	 	 	 	 	 	 	 	 	 	 		
Use of convalescent plasma in 
















Currently,	 the	 COVID-19	 pandemic	 is	 a	 huge	 threat	 to	
global	health.	Several	treatments	have	been	proposed	for	
it	 as	 well	 as	 adjuvant	 treatments	 that	 can	 allow	
strengthening	 of	 the	 immune	 system	 when	 fighting	 the	
disease.	 In	 this	 work,	 we	 review	 the	 use	 of	 plasma	 as	 a	





of	 success.	 For	 example,	 it	 has	 been	 tested	 against	
measles,	 Argentine	 hemorrhagic	 fever,	 influenza,	
chickenpox,	 cytomegalovirus	 infections,	 parvovirus	 B19	
as	 well	 as	 in	 the	 Middle	 East	 Respiratory	 Syndrome	
(MERS)	caused	by	a	specific	coronavirus,	and	in	the	H1N1	
and	H5N1	influenza	variants	(Marano	et	al.	2016).	
The	 current	 coronavirus	 disease	 2019	 (COVID-19)	
pandemic	has	caused	a	lot	of	economic	and	human	losses	
(Burlacu	 et	 al.	 2020;	 Briggs	 et	 al.	 2021);	 this	 poses	 a	
challenge	 to	 public	 health	 systems	 around	 the	 world	 in	
trying	to	contain	the	damage	that	this	terrible	disease	has	
generated.	 On	 the	 other	 hand,	 the	 scientific	 community	
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has	been	immersed	in	an	unprecedented	race	to	find	new	
therapeutic	options	 (Attia	et	 al.	2021).	Given	 the	 current	
world	 panorama,	 the	 convalescent	 plasma	 is	 seen	 as	 a	
therapeutic	 alternative	 in	 patients	 infected	 by	 SARS-
CoV-2.		
COVID-19	overview	
SARS-CoV-2	 (a	 positive	 single-stranded	 RNA	 virus)	 has	
been	seen	to	alter	the	normal	immune	response,	making	it	
deficient	 and	 creating	 an	 uncontrolled	 inflammatory	
response,	 especially	 in	 patients	 with	 severe	 or	 critical	
illness.	 These	 patients	 might	 exhibit	 lymphopenia,	
lymphocytic	dysfunction,	and	abnormalities	in	monocytes	
and	 granulocytes,	 as	well	 as	 elevated	 levels	 of	 cytokines	
and	an	increase	in	immunoglobulin	G	(Yang	et	al.	2020).	
Virus	 transmission	 between	 humans	 is	 through	 the	
respiratory	 secretions	 of	 infected	 people,	 especially	
during	 expulsion	 by	 coughing	 or	 sneezing,	 of	 small	
droplets	 and	 aerosols	 that	 can	 cross	 the	 air.	 The	 clinical	
picture	of	COVID-19	can	manifest	a	wide	variety	of	clinical	
symptoms,	 from	 an	 asymptomatic	 patient	 to	 those	 with	
multiple	 systemic	 compromises,	 respiratory	 failure,	 and	
death	(Tay	et	al.	2020;	Lewis	2020).	
In	 January	 2020,	 the	 World	 Health	 Organization	
(WHO)	declared	SARS-CoV-2	a	global	emergency.	The	first	
case	 reported	 in	 Mexico	 was	 on	 February	 28,	 2020.	 By	
January	 30,	 2021,	 the	 Johns	 Hopkins	 University	 of	
Medicine,	 through	 the	 Coronavirus	 Resource	 Center,	
reported	 102,257,414	 cases	 of	 people	 infected	 by	 SARS-
CoV-2	worldwide	and	1,841,893	cases	in	Mexico,	of	which	
156,579	have	died	from	COVID-19,	placing	Mexico	in	3rd	




Plasma	 is	 the	 liquid	 component	 of	 the	whole	 blood.	 It	 is	
preferably	 frozen	 within	 the	 first	 six	 hours	 after	 being	
obtained	in	a	quantity	between	150	ml	and	up	to	600	ml.	
Plasma	 contains	 normal	 levels	 of	 stable	 clotting	 factors,	
albumin,	 and	 immunoglobulins	 (Storch	 et	 al.,	 2019).	
Therapeutic	 plasmapheresis	 is	 the	 process	 of	 separating	
and	 removing	 the	 plasma	 from	other	 components	 of	 the	
blood	 and	 is	 considered	 an	 adjunctive	 treatment	 for	
diseases;	 it	 is	 based	 on	 removing	 substances	 such	 as	




divided	 into	 4	 components	 and	 separated	 into	 layers	 by	
their	 different	 densities;	 it	 is	 commonly	 performed	 by	
chemists,	 and	 its	 advantage	 is	 that	 there	are	no	 limits	 to	
the	 size	 of	 the	 molecules	 that	 are	 being	 removed.	 With	
filtration	plasmapheresis,	all	blood	passes	through	a	filter	
to	separate	plasma	components	into	red	blood	cells,	white	
blood	 cells,	 and	 platelets,	 it	 is	 commonly	 performed	 by	
nephrologists	and	intensivists	(Nguyen	et	al.,	2012).	
Plasma	 therapy	 is	 generally	 indicated	 to	 replace	 the	
deficiency	of	coagulation	factors	before	invasive	surgeries	
where	there	is	a	risk	of	severe	bleeding	or	in	cases	where	
the	 concentration	 of	 the	 specific	 factor	 to	 be	 replaced	 is	
not	enough.	 In	 these	circumstances	 the	 requirements	 for	
an	effective	plasma	therapy	are	laboratory	confirmation	of	





The	 transfusion	 is	 carried	 out	 intravenously	 using	
peripheral	 veins	 with	 a	 transfusion	 device	 that	 contains	
170-210	 micron	 filters	 to	 retain	 clots.	 Several	 units	 of	
plasma	can	be	 transfused	using	 the	same	 transfusion	set	
(4	 plasma	 for	 therapeutic	 use,	 2009).	 In	 Mexico,	 before	
the	 transfusion,	 tests	 such	 as	 blood	 group	 and	 RH,	 HIV	
serology,	hepatitis	B,	and	C	viruses	and	syphilis	should	be	
done	(Secretaría	de	Salud,	2007)	but	certainly,	as	in	other	




antibodies	 against	 a	 specific	 antigen;	 these	 antibodies	
together	with	the	immune	system	respond	to	an	infection	
caused	 by	 that	 pathogen	 (Berry	 and	 Gaudet,	 2011).	
However,	 the	 antibodies	 production	 requires	 time,	 and	
every	 human	 being	 has	 a	 different	 response.	 For	 this	





the	 Nobel	 Prize	 in	 Medicine/Physiology	 for	 his	 work	 in	
serum	 therapy,	 especially	 testing	 its	 application	 against	
diphtheria.	 This	 opened	 a	 new	 path	 in	 the	 domain	 of	




passive	 immunity	 concepts,	 establishing	 that	 what	 is	
transmitted	 through	 the	 plasma	 are	 antibodies	 that	 the	
donor	 has	 generated	 against	 certain	 pathology	 towards	
the	 recipient.	 Based	 on	 these	 findings,	 the	 treatment	 of	
multiple	 pathologies	 evolved	 (Nobel	 Prize	 in	 Physiology	
or	Medicine,	1901).	
The	 use	 of	 convalescent	 plasma	 is	 a	 passive	
immunization	 strategy	 that	 has	 been	 used	 in	 the	
prevention	and	treatment	of	epidemic	infections	for	more	
than	100	years.	 In	1907,	 it	was	used	 in	 Italy	 for	 the	 first	
time	 to	 protect	 children	 infected	 with	 measles	 and	 in	
1916	 to	 treat	 acute	 paralysis	 during	 a	 polio	 outbreak	 in	
New	 York,	 in	 both	 cases	 proving	 their	 efficacy	 (Marson,	






should	be	administered	as	 early	 as	possible	 to	maximize	
their	effectiveness,	because	there	is	the	possibility	that	the	
number	of	antigens	is	much	higher	than	antibodies	when	
the	 disease	 becomes	 severe,	 thus	 reducing	 its	 effect	
(Samad	et	al.,	2020).	




COVID-19	 such	 as	 social	 distancing,	 hygiene,	 and	
protection	with	face	masks	(Moran	et	al.	,2021),	scientists	
have	been	 looking	 for	cures	 for	 this	disease	and	 in	2021,	
vaccines	 from	 different	 countries	 were	 approved	 for	
massive	 use.	 However,	 convalescent	 plasma	 is	 still	 an	
option	in	the	contention	of	this	disease.	
In	 summary,	 it	 has	 been	 observed	 that	 the	 use	 of	
convalescent	 plasma	 reduces	 the	 mortality	 rate,	
decreasing	 the	 viral	 load	 and	 improving	 the	 clinical	
condition;	 it	 not	 only	 neutralizes	 the	 pathogen	 but	 also	
provides	 immunomodulatory	 properties	 that	 allow	
controlling	 the	 inflammatory	 cascade	 that	 is	 created	due	
to	the	infectious	agent	(Rojas	et	al.,	2020).	
Potential	convalescent	plasma	donors	must	go	through	
a	 pre-donation	 check-up	 to	 ensure	 that	 they	 fulfill	 the	
appropriate	 conditions:	 They	 must	 be	 between	 18-65	
years	 old,	 without	 symptoms,	 and	 a	 negative	 test	 for	
COVID-19	 (qPCR	 or	 serology)	 after	 14	 days	 of	 recovery	
(this	 test	 must	 be	 performed	 again	 48	 hours	 later),	 a	
negative	 test	 for	COVID-19	by	pharyngeal	 swab	and	/	or	
blood	 sample	 at	 the	 time	 of	 the	 donation,	 neutralizing	
antibody	 titer	 greater	 than	 1:320,	 and	 a	 check	 that	 the	
donor	is	free	of	infectious-contagious	diseases.		
The	 recommended	procedure	 for	 obtaining	 plasma	 is	
apheresis	 by	 centrifugation;	 the	 plasma	 administration	
range	 is	 between	 200-500	 ml ;	 current ly	 the	
recommendation	is	to	administer	3	ml/kg/dose	in	2	days.	
The	 efficacy	 of	 this	 procedure	 relies	 on	 the	 neutralizing	
antibodies	 concentration	 in	 the	 donor	 plasma;	 these	
antibodies	bind	to	the	spike	1	receptor	binding	protein	of	
the	coronavirus	(S1-RBD)	and	to	the	terminal	domain	S1	
and	 S2,	 inhibiting	 their	 entry	 and	 limiting	 viral	
amplification,	 in	 addition	 to	 other	 antibody-mediated	
pathways	 such	 as	 complement	 activation,	 cellular	
cytotoxicity,	 and	 phagocytosis	 that	 can	 promote	 the	




of	 the	 blood	 components,	 clearly	 indicated	 on	 it:	
"Convalescent	plasma	 for	use	 in	 studies	 related	 to	SARS-
CoV-2".	The	expiration	date	will	be	in	accordance	with	the	
storage	practices	of	blood	banks;	 for	 fresh	 frozen	plasma	
being	1	year	from	the	date	of	collection	if	stored	at	-80ºC	
or	less	and	must	be	frozen	within	8	hours	after	collection.	
In	 clinical	 trials,	 one	 unit	 of	 plasma	 (200	ml)	 is	 used	
for	prophylaxis	and	two	units	(400	ml)	for	treatment.	The	
duration	 of	 the	 effectiveness	 of	 the	 antibodies	 decreases	
through	 time.	 It	 is	 estimated	 to	 last	 from	weeks	 up	 to	 a	







Given	 the	 current	 world	 panorama,	 in-depth	 research	 is	
needed	 to	assess	 the	benefits	of	a	new	treatment	option.	
Convalescent	 plasma	 has	 been	 used	 as	 a	 therapeutic	
alternative	 since	 ancient	 times.	 The	 use	 of	 plasma	 as	 a	
therapeutic	modality	to	treat	infectious	diseases	has	been	
known	for	more	than	100	years,	being	of	great	benefit	 in	
certain	 pathologies,	while	 in	 others	 being	moderately	 or	
not	effective.	
The	benefits	of	this	therapy	are	still	uncertain	against	
COVID-19	 although	 the	 evidence	 seems	 to	 indicate	 a	
clinical	 improvement	 while	 its	 risks	 are	 the	 same	 as	 in	
other	 cases	 of	 transfusions,	 that	 is,	 allergic	 reactions,	
possibility	 of	 transmission	 of	 infectious	 agents,	
anaphylaxis	 reactions,	 acute	 lung	 damage	 as	 well	 as	
h e m o l y s i s	 a m o n g	 o t h e r s	 ( h t t p s : / /
www.covid19treatmentguidelines.nih.gov/anti-sars-
cov-2-antibody-products/convalescent-plasma/	 2020).	
Overall,	plasma	donation	 is	 safe	 for	patients	and	adverse	
effects	are	rare.	
The	 Food	 and	 Drug	 Administration	 (FDA)	 has	
approved	 the	 emergency	use	 of	 the	 convalescent	 plasma	






to	 be	 effective	 in	 reducing	 mortality	 in	 hospitalized	
patients	(FDA).	
In	South	America,	several	countries	have	implemented	
specific	 protocols	 to	 administer	 convalescent	 plasma	 to	
people	 with	 COVID-19.	 Those	 developed	 by	 Bolivia	 and	
Venezuela	 (Nina	 Garcia	 &	 Cussi	 Coronel,	 2020;	 Sánchez	
et	 al.,	 2020)	 attract	 attention.	 In	Mexico,	 there	 are	 some	











Medicine	 as	 science	 has	 had	 the	 ultimate	 goal	 of	
safeguarding	 human	 health	 by	 all	 means	 but	 always	
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respecting	 the	 four	 principles	 of	 bioethics:	 autonomy,	
beneficence,	justice,	and	non-maleficence	(Holm	2002).	In	
relation	 to	 COVID-19	 and	 convalescent	 plasma,	 one	
paradoxical	situation	we	are	 facing	nowadays	 is	 that	 this	
blood	product	is	stored	in	blood	banks	without	being	used	
due	 to	 the	 lack	 of	 authorized	 research	 protocols	 in	
hospitals	where	 it	 is	 obtained.	 For	 example,	 the	 average	
activity	of	the	Blood	Bank	of	the	“Mónica	Pretelini	Sáenz”	
Maternal-Perinatal	 Hospital	 (HMPMPS),	 Health	 Institute	
of	the	State	of	Mexico	(ISEM),	Toluca,	Mexico,	shows	that	




SARS-CoV-2	 has	 donated	 blood	 or	 plasma	 that	 has	 been	
stored	and	administered	to	a	patient	without	knowing	this	
condition	because	the	COVID-19	test	 is	not	a	routine	test	
before	 the	 donation.	 Furthermore,	 we	 can	 assume	 that	
this	phenomenon	is	occurring	throughout	the	world.	
Taking	into	account	the	bioethical	principles	of	respect	
for	 autonomy,	 nonmaleficence,	 beneficence,	 and	 justice,	
imagine	 the	 circumstance	 in	 which	 there	 is	 one	 patient	
with	COVID-19	 intubated	 in	an	 Intensive	Care	Unit	 (ICU)	
with	a	mortality	of	60%	and	 the	physician	 in	 charge	has	
the	 possibility	 to	 ask	 for	 plasma	 donors	 from	 recovered	
patients	and	all	but	a	physician	agree	to	give	a	single	dose	
of	 the	 convalescent	 plasma;	 due	 to	 the	 discordance	 the	
plasma	cannot	be	 infused.	The	opposed	physician	argues	
that	the	convalescent	plasma	has	not	been	added	into	an	
international	 flowchart	 to	 treat	 COVID-19.	 With	 a	
COVID-19	 mortality	 higher	 than	 60%	 when	 intubated	
until	when	do	we	have	 to	wait	 for	 a	 randomized,	double	
blind	trial	with	convalescent	plasma	before	trying	to	get	a	
reduction	 in	 the	mortality	using	convalescent	plasma?	At	









clear,	 as	 the	 treatment	with	 convalescent	 plasma	 is	 well	
known	and	under	usual	conditions	the	risks	are	low.	
Under	 substantial	 uncertainty	 during	 aggressive	 and	
unknown	diseases,	waiting	too	long	for	the	perfect	clinical	
a ssay	 cou ld	 condemn	 hundreds	 o f	 pa t ien ts .	
Notwithstanding,	the	scientific	evidence	on	the	use	of	this	
therapy	 is	 still	 limited.	 However,	 multiple	 studies	 are	
currently	 being	 carried	 out	 throughout	 the	world	 on	 the	
use	 of	 convalescent	 plasma	 for	 the	 treatment	 of	 SARS-
CoV-2	infection	(Table	1).	It	is	expected	that	the	results	of	
these	 investigations	 will	 begin	 to	 appear	 in	 2021	
(Wooding	&	Bach,	2020).	
Conclusion	
Convalescent	 plasma	 can	 be	 a	 therapeutic	 alternative	 in	
patients	 with	 COVID-19	 that	 improves	 symptoms	 and	
prognosis,	 and	 it	 does	 not	 have	 a	 statistically	 significant	
adverse	 effect	 on	mortality	 rates.	 Based	 on	 the	 evidence	
mentioned	above,	convalescent	plasma	against	COVID-19	
should	be	considered,	at	least	as	a	compassionate	therapy,	
particularly	 in	 emergency	 cases	 of	 patients	 admitted	 to	
hospitals,	 despite	 the	 absence	 of	 an	 authorized	protocol,	
considering	 that	 the	 attempt	 to	 safeguard	 life	 is	 more	
important	 than	 the	 existing	 technical	 limitations.	 We	
strongly	 recommend	 to	 health	 institutions	 that	 they	 can	
facilitate	 the	 prompt	 approval	 of	 the	 different	 protocols	
necessary	to	start	the	use	of	this	complementary	therapy.	
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